Mabion Osinko

Mitä Mabion tekee? Mabion SA is a biotechnology company based in Konstantynow Lodzki, Poland, operating within the Health Care sector. The company specializes in the development and manufacturing of biotech drugs, particularly focusing on humanized monoclonal antibodies (mAbs) technology. Mabion SA has 255 employees and went public through an IPO on August 10, 2010. The company's website is https://www.mabion.eu/. Mabion SA operates a Research and Development Center within the Special Economic Zone in Lodz, Poland. The company's product focus includes oncology drugs for treating blood cancer, lymphomas, leukemias, rheumatoid arthritis, and breast cancer. Mabion SA was founded by four pharmaceutical companies—Celon Pharma Ltd, Polfarmex Co, Genexo Ltd, and IBSS Biomed Co—and two biotechnology research and development firms—BioCentrum Ltd and Biotech Consulting Ltd. The company's headquarters are located in Konstantynow Lodzki, in the Lodzkie region of Poland. Mabion SA is listed on the Warsaw Stock Exchange under the ticker MAB.WA and has the ISIN PLMBION00016. The company's activities are centered around the development of innovative biotechnological drugs, with a strong emphasis on therapeutic applications in oncology and autoimmune diseases. The firm's R&D operations are conducted within a dedicated facility in the Lodz Special Economic Zone, supporting its focus on cutting-edge biopharmaceutical solutions. Mabion on yksi Eulopoolissa suosituimmista yrityksistä.